- to assess the overall safety of Avelumab administered as adjuvant treatment in patients with high-risk primary triple negative breast cancer who have completed treatment with curative intent including surgery of the primary tumor, neo- or adjuvant chemotherapy, and (if indicated) radiotherapy.